E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patient concerned by this trial are patients who will undergo a cataract surgery |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In this study, the primary objective will be the measurement of the concentration of azithromycin in aqueous humour into the operated eye of patient undergoing cataract surgery |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients will be eligible for inclusion if all these criteria are respected: - Male or female from 18 to 90 years old - Signed and dated informed consent. - Senile or pre-senile uncomplicated cataract. - Scheduled to undergo cataract surgery
|
|
E.4 | Principal exclusion criteria |
Patients fulfilling at the inclusion visit ONE OR MORE of the following non inclusion criteria will not be included in the study:
Ophthalmic non-inclusion criteria (in either eye) None of the following criteria IN EITHER EYE: - Surgical conditions in the eye to be operated: ÿ Combined surgery. ÿ Other cataract aetiologies than senile or pre-senile cataract. - Non-surgical conditions in the eye to be operated: ÿ Dacryocystitis and all others pathologies of tears drainage system. ÿ Inflammatory ocular disease (uveitis, herpetic keratitis). ÿ Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration and superficial punctuate keratitis). ÿ History of ocular traumatism, infection or inflammation within the last 3 months. - Ophthalmic condition in the contra lateral eye: ÿ Best corrected visual acuity < 1/10. ÿ Patient already included in the study for phakoexeresis. ÿ History of surgical complication - Ophthalmic condition in either eye: ÿ Presence of glaucoma and/or ocular hypertension history 9.3.2.2 Systemic/non ophthalmic non-inclusion criteria [2.2] None of the following criteria: - General history: ÿ Diabetes not controlled, ÿ Infectious diseases, ÿ Immunosuppressive diseases, ÿ Any other medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine neoplasic, haematological diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc... and/or any complicating factor or structural abnormality judged by the investigator to be incompatible with the study. - Allergic history: ÿ Known hypersensitivity to one of the components of the study medications or to any other macrolide antibiotic or to test products, ÿ Allergic rhinitis. Specific non-inclusion criteria for women - Pregnancy, lactation. - Women without an effective method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, patch). or - Women not hysterectomised, menopaused or surgically sterilized. Non-inclusion criteria related to general conditions - Inability of patient and/or relatives to understand the study procedures and thus inability to give informed consent - Non compliant patient and/or relatives (e.g. not willing to attend the follow-up visits, way of life interfering with compliance). - Participation in another clinical study. - Already included once in this study. - Ward of court. - Patient not covered by the Social Security scheme.
Non-inclusion criteria related to previous and concomitant medications / non-product therapies
Patient using any of the following previous and concomitant medication / treatment (according to the described periods) will not be included in the study: -4 weeks before the surgey date: Systemic therapies: corticoid ans immunosuppressive treatment Systemic azythromycin -15 days before the surgery Other systemic antibiotic Topical ocular therapy in the eye to be operated other than tears substitutes (antibiotic, corticoid, antiallergic, antiseptic,....) (exept for antiseptic, -7 days before for contact lenses -3 days before for tear substitutes
|
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial will be last visit last patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |